Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trialGlobeNewsWire • 03/23/23
Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitisGlobeNewsWire • 03/21/23
Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitisGlobeNewsWire • 03/18/23
Sanofi to slash U.S. insulin prices in 2024 after similar cuts by Eli Lilly and Novo NordiskCNBC • 03/16/23
Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insuranceGlobeNewsWire • 03/16/23
Week Ahead: Banking Crisis, Inflation Reports, and Big Pharma AcquisitionsZacks Investment Research • 03/13/23
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash dealProactive Investors • 03/13/23
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi DealInvestors Business Daily • 03/13/23
Press Release: Sanofi to acquire Provention Bio, adding to portfolio TZIELD, the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D)GlobeNewsWire • 03/13/23
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV RaceInvestors Business Daily • 03/08/23